Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3554 participants.

Also called NCT02892149

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,554 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02892149
  • EudraCT 2016-001360-11
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, France, Germany, Israel, Italy, Mexico, Poland, Portugal, Russia, Serbia, South Korea, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02892149. Randomized; no masking; primary purpose treatment. Start 2016-08 (actual); primary completion 2020-01-16 (actual). Results posted on 2022-06-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Condition
Anemia
Condition
Dialysis-Dependent Chronic Kidney Disease
Intervention (Drug)
Vadadustat
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02892149
Content hash
35d149ed3f9a413e0bb1e44b95cbc2d9ca28e6f05de91d9cd6c1a73c4941f599